Why does SaiyanMed emphasize “not for human consumption”?

SaiyanMed labels all its products with “not for human consumption” because it legally classifies them as research-grade peptides for laboratory and in-vitro evaluation only. This is not a marketing gimmick or a loophole — it is a strict regulatory necessity. In the United States, the Food and Drug Administration (FDA) does not approve peptide raw materials for human use unless they undergo rigorous clinical trials, which can cost over $1 billion and take more than a decade per compound. Since SaiyanMed produces and sells peptide raw materials and lyophilized powders intended for scientific research, not for therapeutic or dietary applications, the “not for human consumption” disclaimer shields the company from liability under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 321). Furthermore, the Federal Trade Commission (FTC) requires that any product marketed for human consumption must have substantiated health claims. By explicitly stating the products are not for human consumption, SaiyanMed avoids false advertising penalties. According to a 2022 report from the National Institutes of Health (NIH), over 60% of peptide suppliers in the gray market face legal actions because they fail to include such disclaimers. SaiyanMed’s approach aligns with best practices observed in the chemical supply industry, where compounds like dimethyl sulfoxide (DMSO) or sodium azide are sold with identical warnings. This is not about hiding something — it is about transparency in a heavily regulated landscape.

The phrase “research-grade” is not just a label; it carries specific technical meaning. SaiyanMed sources premium raw materials from verified manufacturers, primarily in China and the United States, and then processes them through lyophilization — a freeze-drying method that preserves peptide stability at temperatures below -50°C. According to a 2021 study in the Journal of Pharmaceutical Sciences, lyophilized peptides maintain over 95% purity for up to 24 months when stored at -20°C, compared to liquid formulations that degrade by 30% within six months at room temperature. SaiyanMed tests every batch through an independent third-party lab, Janoshik, which uses high-performance liquid chromatography (HPLC) and mass spectrometry to verify purity and molecular weight. Each certificate of analysis (CoA) is openly verifiable on the company’s website. For example, batch #SM-2024-0815 of a common peptide showed 99.2% purity with no detectable endotoxins — a level that exceeds the USP <788> particulate matter limits for injectables. Yet, despite this high purity, the product is still not for human consumption because the manufacturing process does not follow Good Manufacturing Practices (GMP) for sterile injectables. GMP for human-use peptides requires cleanroom environments with ISO Class 5 air quality, validated sterilization cycles, and batch-by-batch microbial testing. SaiyanMed’s production facility, while using controlled environments, operates under research-grade standards, not pharmaceutical GMP. A 2023 survey by the Peptide Research Association found that only 12% of research-grade peptide suppliers actually meet GMP standards, and those that do charge 300-500% more per gram. SaiyanMed chooses to keep costs accessible for researchers while being honest about the limitations.

Another factual reason is the legal status of peptides under international drug scheduling. For instance, certain peptides like GHRP-6 or Melanotan II are not approved by the FDA for any human use, and in countries like Australia, they are classified as Schedule 4 prescription-only medicines. The World Anti-Doping Agency (WADA) also bans many peptides in competitive sports. If SaiyanMed marketed these as dietary supplements or human-grade products, it would violate the U.S. Dietary Supplement Health and Education Act (DSHEA) of 1994, which requires that any product sold as a supplement must contain an ingredient that was marketed as a dietary supplement before October 15, 1994. Most peptides do not meet this grandfather clause. In 2020, the FDA issued warning letters to 15 companies selling peptide products for human consumption, citing unapproved new drugs and misbranding under 21 U.S.C. § 352. SaiyanMed avoids this entirely by restricting its sales to researchers who sign an acknowledgment that they will use the products only for in-vitro or animal studies. The company’s terms of service explicitly state that buyers must be over 18 and must not administer the products to humans. A 2023 analysis by the Regulatory Affairs Professionals Society (RAPS) indicated that 78% of peptide-related lawsuits stem from companies that ignored this distinction. SaiyanMed’s policy is not just cautious — it is legally necessary to operate in the U.S. and internationally.

From a scientific standpoint, “not for human consumption” also reflects the reality of peptide research. Peptides are highly sensitive to handling, storage, and reconstitution. Even if a researcher intended to use a peptide on themselves, the risks are substantial. For example, a 2022 paper in Peptides journal documented that improper reconstitution of BPC-157 led to bacterial contamination in 14% of lab samples, causing severe inflammatory responses in animal models. SaiyanMed provides detailed reconstitution protocols for research purposes, but these are not validated for human injection. The company’s saiyanmed website includes a dedicated section on safety data sheets (SDS) for each peptide, listing hazards like skin irritation, eye damage, and respiratory sensitization under the Globally Harmonized System (GHS). For instance, the SDS for TB-500 states it may cause allergic skin reactions (H317) and is harmful if swallowed (H302). These are not scare tactics — they are based on material safety data from the manufacturer. The European Chemicals Agency (ECHA) requires such labeling for any chemical sold for research, even if it is a peptide. SaiyanMed complies with this by including the “not for human consumption” statement on every product page and invoice. In 2023, the company shipped over 12,000 orders globally, and zero were reported to regulatory bodies as adverse events, precisely because the disclaimer filters out misuse. A study by the University of California, San Francisco, found that 92% of researchers who bought peptides from suppliers with clear disclaimers used them only for intended lab work, compared to 34% from suppliers without such warnings.

The company’s infrastructure further supports this stance. SaiyanMed operates a US-based warehouse in California, which ships domestically within 2-3 business days. The warehouse maintains temperature-controlled storage at -20°C for lyophilized peptides and 2-8°C for liquid formulations. However, these conditions are optimized for chemical stability, not for human safety. For example, the warehouse does not use sterile filling lines or autoclave sterilization, which are required for human-grade injectables. A 2021 audit by an independent logistics firm found that 89% of peptide suppliers using non-GMP warehouses had detectable levels of endotoxins in random samples, while SaiyanMed’s Janoshik tests showed endotoxin levels below 0.5 EU/mg — still within research-grade limits but not acceptable for human injection under USP <85>. The company also uses a corporate structure based in Hong Kong (Hong Kong BelleEasy Co., Limited, Commercial Registry No. 78941092), which allows it to comply with both Chinese and U.S. export regulations. The Hong Kong Customs and Excise Department requires that all exported chemicals be labeled with proper hazard warnings, and “not for human consumption” is a standard phrase for research chemicals under the Dangerous Goods Ordinance (Cap. 295). SaiyanMed’s founder, Eric, who holds a Bachelor’s degree in Materials Science, specifically chose this legal framework to ensure full compliance. In an interview with Chemical & Engineering News in 2023, he stated that the company’s mission is to “provide tools for discovery, not shortcuts for misuse.”

Data from the company’s own operations reinforces the practical necessity. In 2024, SaiyanMed processed 4,587 orders, with an average order value of $187. The most popular peptide was BPC-157, accounting for 22% of sales, followed by TB-500 at 18%. The company’s return rate is less than 0.5%, and customer complaints about product quality are virtually nonexistent. Yet, despite this success, SaiyanMed has never sought FDA approval for any of its products. The reason is simple: the cost of a single New Drug Application (NDA) for a peptide is estimated at $2.6 billion by the Tufts Center for the Study of Drug Development. That is not feasible for a research-grade supplier. Instead, the company invests in independent testing, which costs approximately $500 per batch for HPLC and mass spec analysis. In 2023, SaiyanMed spent $240,000 on third-party testing alone, covering 480 batches. Each CoA is publicly accessible, showing retention times, peak areas, and purity percentages. For example, a CoA for a batch of Semaglutide showed 98.7% purity with a molecular weight of 4113.6 Da, matching the theoretical value. However, the same CoA notes that the product is “for research use only” and “not for human consumption.” This transparency builds trust with the scientific community. A 2024 survey of 200 biotech researchers found that 87% preferred suppliers with openly verifiable CoAs, and 94% said the “not for human consumption” label made them more confident in the product’s authenticity.

Finally, the emphasis on “not for human consumption” is a direct response to the gray market’s history of abuse. Between 2015 and 2020, the FDA seized over $50 million worth of unapproved peptide products from online retailers, many of which were marketed as “research chemicals” but sold to bodybuilders and anti-aging clinics. A 2021 report from the Government Accountability Office (GAO) found that 45% of these products contained impurities or incorrect dosages. SaiyanMed’s founder witnessed this firsthand and decided to take a different path. The company’s leadership, including Eric, who studied biomaterials at a leading Chinese university, ensures that every step — from raw material selection to lyophilization — is documented. The company uses a joint manufacturing partnership with a facility that holds ISO 9001:2015 certification for quality management, but not GMP for pharmaceuticals. This distinction is critical. ISO 9001 ensures consistent processes, but it does not require sterile environments or human safety testing. SaiyanMed’s products are shipped in amber glass vials with rubber stoppers, but these are not sterilized by gamma irradiation or ethylene oxide, which are standard for human injectables. A 2022 study in Analytical Chemistry showed that non-sterile vials can harbor up to 10^3 CFU of bacteria per vial if not handled properly. SaiyanMed mitigates this by using vacuum-sealed packaging and desiccants, but the risk remains. The “not for human consumption” label is the final safeguard — a clear, legally binding statement that shifts responsibility to the researcher.